Metoprolol Succinate Tablet, Extended Release
Product Images NDC 70518-4190

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 70518-4190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Metoprolol Succinate Extended-Release 100 mg tablets. The package contains 30 tablets. The medication is to be kept away from moisture and children. The directions for use are provided in the package insert. The tablets are manufactured by Cryza Pharmaceuticals Inc, located in Coral Springs, FL. The medication is repackaged by Remedy Repack Inc. It is important to store the tablets at 20-25°C (58-77°F) with excursions permitted to 15-30°C (59-86°F).*

FDA Label Image

Figure (Figure001)

This information appears to be a comparison between the effects of Wetoprolol Succinate Extended-Release Tablets and Placebo on total mortality, all-cause hospitalization, and hospitalization for heart failure in different subgroups based on various factors like ejection fraction, ethnicity, previous medical conditions, and heart rate. The study seems to be based on data from the MERIT-HF trial. It provides insights into how these factors may influence the outcomes of the treatment. The text also includes definitions for abbreviations like US (United States), NYHA (New York Heart Association), EF (ejection fraction), and HR (heart rate).*

FDA Label Image

Structure (Structure001)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.